, Volume 73, Issue 1, pp 45–54 | Cite as

Subcutaneous Bortezomib

In Multiple Myeloma
Adis Drug Profile


A subcutaneous formulation of bortezomib is now indicated in the EU and the US for the treatment of patients with multiple myeloma. This article reviews pharmacological, therapeutic efficacy and tolerability data relevant to the utilization of subcutaneous bortezomib (Velcade®) in the treatment of patients with multiple myeloma. In a randomized, nonblind, phase III study, subcutaneous bortezomib was noninferior to intravenous bortezomib in the treatment of adults with relapsed multiple myeloma, as determined by the overall response rate after four cycles of therapy (primary endpoint). No significant differences between the subcutaneous and intravenous bortezomib formulations were observed in the median time to first response, median progression-free survival, median time to progression and 1-year overall survival. Compared with intravenous bortezomib, subcutaneous bortezomib confers a significant advantage with respect to the incidence of peripheral neuropathy (all grades, grade ≥2 and grade ≥3). As a consequence, it provides a new treatment option for patients with multiple myeloma, particularly those with pre-existing neuropathy or at a high risk of developing peripheral neuropathy.


  1. 1.
    Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60.PubMedCrossRefGoogle Scholar
  2. 2.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. 1.2013 [online]. http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed 26 Nov 2012.
  3. 3.
    Mateos M-V. Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol. 2011;12(5):410–1.PubMedCrossRefGoogle Scholar
  4. 4.
    Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69(7):859–88.PubMedCrossRefGoogle Scholar
  5. 5.
    Janssen-Cilag International NV. Velcade 1 mg powder for solution for injection: summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf. Accessed 2 Nov 2012.
  6. 6.
    Millennium Pharmaceuticals Inc. Velcade® (bortezomib) for injection: US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021602s027lbl.pdf. Accessed 14 Nov 2012.
  7. 7.
    Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005;5(1):18.PubMedCrossRefGoogle Scholar
  8. 8.
    Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–59.PubMedCrossRefGoogle Scholar
  10. 10.
    Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010;16(16):4094–104.PubMedCrossRefGoogle Scholar
  11. 11.
    Zangari M, Terpos E, Zhan F, et al. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012;38(8):968–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.[published erratum appears in Lancet Oncol. 2011 Jun; 12(6):522]. Lancet Oncol. 2011;12(5):431–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized, phase 3 study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Millennium Pharmaceuticals Inc. A study of subcutaneous and intravenous Velcade in patients with previously treated multiple myeloma [ClinicalTrials.gov identifier NCT00722566]. US National Institutes of Health, ClinicalTrials.gov [online].http://clinicaltrials.gov. Accessed 26 Nov 2012.
  16. 16.
    Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Durie BG, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086–95.PubMedCrossRefGoogle Scholar
  20. 20.
    Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895–903.PubMedCrossRefGoogle Scholar
  21. 21.
    Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature [published erratum appears in Blood. 2009;113(18):4478]. Blood. 2008;112(5):1593–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Mateos M-V, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Ostendorf W. Administration of parenteral medication. In: Perry A, Potter P, Elkin MK, editors. Nursing interventions & clinical skills. 5th ed. St Louis: Elsevier Mosby; 2012. p. 541–83.Google Scholar
  25. 25.
    Fundamentals of administration. In: Polovitch M, Whitford J, Olsen M, editors. Chemotherapy and biotherapy guidelines and recommendations for practice. 3rd ed. Pittsburgh: Oncology Nursing Society; 2009. p. 73–104.Google Scholar
  26. 26.
    Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20(17):3719–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations